Journal info
|
||
Select Journal
Journals
Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics Neoplasma 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Neoplasma Vol.50, p.41-46, 2003 |
||
Title: Serum leptin, prolactin and vascular endothelial growth factor (VEGF) levels in patients with breast cancer | ||
Author: U., COSKUN ; N., GUNEL ; F.B., TORUNER ; B., SANCAK ; E., ONUK ; O., BAYRAM ; O., CENGIZ ; E., YILMAZ ; S., ELBEG ; S., OZKAN ; | ||
Abstract: Angiogenesis plays an important role in tumor growth and metastasis in solid
tumors. VEGF is an important regulator of tumor angiogenesis. Both leptin and
prolactin have also been suggested to have roles in the regulation of angiogenic
process. In our study, we measured serum leptin, prolactin and VEGF levels in 30
metastatic, 55 non-metastatic breast cancer patients and 25 control subjects.
Serum leptin levels were found to be similar in non-metastatic (38.1+/-19.5
ng/ml), metastatic patients (39.6+/-16.3 ng/ml) and control subjects
(35.6+/-13.9 ng/ml) (p>0.05). There was no statistically significant difference
between patients with visceral metastasis (44.0+/-16.8 ng/ml) and patients with
bone metastasis (35.2+/-15.0 ng/ml) (p>0.05). Serum prolactin levels were found
to be similar in non-metastatic (12.2+/-10.7 ng/ml), metastatic patients
(11.6+/-8.2 ng/ml) and control subjects (12.3+/-8.1 ng/ml), (p>0.05). Moreover,
serum prolactin levels were not different in patients with visceral (11.4+/-8.8
ng/ml) and bone metastasis (11.8+/-8.0 ng/ml), (p>0.05). Metastatic patients had
higher serum VEGF levels (249.8+/-154.9 pg/ml), when compared to the
non-metastatic patients (138.7+/-59.3 pg/ml) and control subjects (108.4+/-47.7
pg/ml), (p<0.05). There was no difference in serum VEGF levels in non-metastatic
patients and control subjects (p>0.05). Patients with visceral metastasis
(337.0+/-168.0 pg/ml) had higher serum VEGF levels, when compared to patients
with bone metastasis (162.6+71.8 pg/ml), (p<0.05). Serum VEGF activity may be
used to evaluate angiogenic and metastatic activity in breast cancer patients.
However, serum leptin and prolactin levels does not seem to be related with
angiogenic activity and metastasis in breast cancer patients.
|
||
Keywords: Breast cancer, VEGF, leptin, prolactin, angiogenesis. | ||
Year: 2003, Volume: 50, Issue: | Page From: 41, Page To: 46 | |
|
download file |
|